Related Experiment Video
Updated: Jul 24, 2026
Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 2. General Practices
Published on: October 3, 2016
Current status of pathogen handling in European laboratories: focus on viral inactivation process
Boris Pastorino1, Franck Touret1, Magali Gilles1
1Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
Abstract:
For handling safely infectious agents, European laboratories must comply with specific EC Directives, national regulations and recommendations from the World Health Organization (WHO). To prevent laboratory acquired infections (LAIs) and pathogens dissemination, a key biosafety rule requires that any infectious material (clinical specimens or research samples) manipulated outside a biosafety cabinet (BSC) must be inactivated unless the lack of infectivity is proven. This inactivation process is a crucial step for biosafety and must be guided by a rigorous experimental qualification and validation procedure. However, for diagnostic or research laboratories, this process is not harmonized with common standard operation procedures (SOPs) but based on individual risk assessment and general international guidelines which can pose problems in emergency situations such as major outbreaks or pandemics. This review focuses on viral inactivation method, outlining the current regulatory framework, its limitations and a number of ways in which biosafety can be improved.
Insights
European laboratories must validate viral inactivation methods to prevent laboratory-acquired infections (LAIs) and pathogen spread. Current biosafety protocols lack harmonization, posing risks during outbreaks.
Area of Science:
- Biosafety and Biosecurity
- Virology
- Laboratory Medicine
Background:
- European laboratories must adhere to EC Directives, national regulations, and WHO guidelines for handling infectious agents.
- A critical biosafety rule mandates inactivation of infectious materials manipulated outside biosafety cabinets (BSCs) to prevent laboratory-acquired infections (LAIs) and pathogen dissemination.
- The validation of viral inactivation procedures is essential for laboratory safety.
Purpose of the Study:
- To review current viral inactivation methods in European laboratories.
- To outline the existing regulatory framework and identify its limitations.
- To propose improvements for enhanced biosafety, particularly in emergency situations like pandemics.
Main Methods:
- Literature review of current biosafety regulations and guidelines (EC Directives, WHO).
- Analysis of standard operating procedures (SOPs) for viral inactivation in diagnostic and research laboratories.
- Examination of risk assessment strategies and validation procedures for inactivation methods.
Main Results:
- Current viral inactivation validation processes are not harmonized across laboratories.
- Reliance on individual risk assessments and general guidelines can be problematic during emergencies.
- Existing regulations may not fully address the complexities of rapid inactivation needs in outbreak scenarios.
Conclusions:
- There is a need for harmonized, standardized procedures for viral inactivation method validation.
- Improved biosafety measures are required to address the limitations of current practices, especially during pandemics.
- Further research and development of robust inactivation techniques are crucial for laboratory safety and public health protection.
